CytomX Therapeutics, Inc. Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--CytomX Therapeutics, Inc., a leader in the field of highly targeted monoclonal antibody therapies, today announced the appointment of Hoyoung Huh, M.D., Ph.D., as chairman of the Board of Directors. Former chairman Charles Homcy, M.D., venture partner at Third Rock Ventures, will continue to serve on the Board of Directors.